Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
← catalyst calendarNCT07227012 · readout in 425 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
138estimated
Sites
54
Countries
Japan, Puerto Rico, Taiwan +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-01 | actual | When the study began enrolling |
| Primary completion | 2027-10-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-10-17 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Carcinoma, Hepatocellular
- Hepatocellular Cancer
- Hepatocellular Carcinoma
- Unresectable Hepatocellular Carcinoma
- Liver Neoplasms
- Advanced Hepatocellular Carcinoma
- Metastatic Hepatocellular Carcinoma
Interventions
- Biological: PF-08634404
- Biological: Ipilimumab — also filed as YERVOY
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Adverse Events
measured Through end of study and up to approximately 24 months
Phase 1b: Number of participants with Dose limiting toxicities (DLT)
measured Through 90 days after the last dose of study intervention; Approximately 24 months
Phase 2: Confirmed Overall Response Rate (ORR) using RECIST 1.1 as assessed by investigator
measured Approximately 24 months
Phase 2: Recommended dose of PF-08634404 in combination with ipilimumab
measured Approximately 24 months
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed